Avac Event
Join the International Community of Women Living with HIV Eastern Africa (ICWEA) to discuss the dapivirine vaginal ring, lenacapavir, and cabotegravir. Moderated by Lillian Mworeko and Dr. Lilian Benjamain Mwakyosi, speakers include:
Avac Event
We are excited to invite you to our next TOWN HALL 📣 happening on Tuesday, August 12th at 10 AM EST!
We will be launching two critical resources:
Gain insights from leading voices driving innovation in HIV prevention:
Together, we’ll explore what’s next for long-acting PrEP access, readiness, and demand among key populations globally.
👉 Click the registration link to register now!
Avac Event
Approved in July, lenacapavir for PrEP has tremendous potential to increase access and engagement in the United States, reaching individuals who have been unable to embrace PrEP in its previous formulations. The Choice Agenda and the HIV BLUPrInt team for a deep dive into rolling out lenacapavir (Yeztugo) in the US. Speakers summarized lessons, previewed existing resources, and called for expanded research and practice models that use lenacapavir as a lever to increase HIV prevention access, empowerment, and reach.
Avac Event
This is an ongoing series which occurs on the first Monday of alternating months and moderated by Drs. Patrick Sullivan (Emory Center for AIDS Research) and Kenneth Mayer (Harvard University Center for AIDS Research).
In August, AVAC Executive Director Mitchell Warren presented. Watch the presentation below. Download his slides.
Avac Event
Pre-exposure prophylaxis (PrEP) has emerged as a critical tool in the global HIV prevention response. Despite its proven efficacy, global uptake of oral PrEP has been slower than anticipated, falling short of UNAIDS’ 2025 targets. However, several countries have successfully scaled up oral PrEP, and in the process learnt significant lessons, many of which they are already applying to introduce newer long-acting (LA) PrEP options such as the dapivirine vaginal ring (DVR) and injectable cabotegravir (CAB), and in planning for the introduction of the recently FDA approved twice yearly injectable lenacapavir (LEN).
This webinar aimed to increase momentum around ARV-based HIV prevention by highlighting key opportunities and challenges in scaling up PrEP. Drawing on findings from AVAC’s recent report, “Getting PrEP Rollout Right This Time: Lessons from the Field” (June 2025), the session shared country-level insights and effective interventions to support PrEP adherence and uptake. It reinforced the need for robust, context-driven strategies to accelerate equitable access to these critical prevention tools.
The specific objectives of this webinar were:
Avac Event
The International AIDS Society (IAS) is partnering with the International Society for Vaccines (ISV) to host a virtual mini-symposium on HIV vaccine research and development (R&D). Be sure to take up this unique opportunity to engage with cutting-edge research and contribute to the ongoing dialogue around HIV vaccine development.
Event speakers
Part of ISV’s quarterly Mini Symposia series, this session brings together global leaders in HIV vaccine R&D to share the latest research, challenges and breakthroughs in the field.
Join us in a discussion with:
Avac Event
While the HIV prevention buffet will soon offer a second form of long acting injectable PrEP, ensuring access to all those who can benefit requires innovations in service delivery such as task shifting. In the United States, two Federally Qualified Health Centers (FQHCs) have implemented programming that has expanded clinic capacity, resulting in more individuals being able to choose long acting injectable PrEP. We also heard about innovative efforts to expand PrEP access in South Africa and learned what it takes to integrate task shifting for long-acting PrEP injection programs. We discussed other ways we can collectively innovate to support expanded, sustainable access to all forms of PrEP.
Speakers:
Moderator:
Materials:
Avac Event
On June 11, AVAC hosted a conversation, The Scientific Journey of Lenacapavir: From basic science to clinical development to impact, to explore how US support from NIH for basic science and South Africa’s clinical research infrastructure made possible the development of lenacapavir for PrEP (LEN), a discovery in HIV prevention that went on to be named Science magazine’s 2024 Breakthrough of the Year.
As the field anticipates initial regulatory approval from the US FDA by June 19 and a WHO recommendation in July, Linda-Gail Bekker of the Desmond Tutu Health Foundation, Wes Sundquist of the University of Utah and Mitchell Warren of AVAC underscored how this moment of promise is threatened by sweeping attacks on science, research and the very systems that made the development of LEN possible.
Avac Event
The Towards an HIV Cure programme of IAS – the International AIDS Society – invites you to a webinar, titled “On the road to IAS 2025: Scientific highlights in HIV cure research”.
This webinar will set the scene for the pre-conference, “Co-infections, viral and host diversity: Impact on HIV cure strategies”, taking place on 13 July at IAS 2025, the 13th IAS Conference on HIV Science. It will highlight key scientific developments presented at CROI 2025 and the Keystone Symposia, “HIV Cure: Antiretroviral-Free Control of HIV Infection”, and explore how these findings are shaping the HIV cure field and informing the conversation leading up to IAS 2025.
Confirmed Speakers
Avac Event
Join AVAC and GBGMC for the next “Fight For Our Lives” Emergency Town Hall to learn more about how the recent freeze on US government foreign assistance has impacted the availability of PrEP, including the rollout of injectable cabotegravir for PrEP, and what this means for key populations and LGBTQ+ communities.
This is an ongoing series. Forthcoming times shown are Eastern Time. Find the time in your region here.